Brand Awareness Archives - BioMedWire (BMW)

WednesdayJun 03, 2026 9:00 am

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

BioMedWire Editorial Coverage: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) is advancing its Sapu003 program and Deciparticle(TM) platform as key…

MondayJun 01, 2026 9:00 am

How Advanced Drug Delivery Could Improve Existing Cancer Treatments

BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs. Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) is advancing its Sapu003 program and Deciparticle(TM) platform as part of a larger industry trend focused on scalable nanotechnology-enabled…

WednesdayMay 13, 2026 9:00 am

Real-Time Intoxication Detection Platforms Target Expanding Multibillion-Dollar Healthcare Opportunities

BioMedWire Editorial Coverage: For decades, reliably identifying drug and alcohol impairment has been a persistent problem across industries, from traffic enforcement and occupational safety to clinical medicine and public health. Conventional tools such as breathalyzers, blood draws and urine tests are hampered by their intrusiveness, slow turnaround times or inability to capture real-time impairment, especially when multiple substances are involved. As substance-use patterns shift and the broader societal costs of intoxication continue to mount, the pressure to develop faster, less invasive, and more scalable detection methods is intensifying. MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) (Profile) is taking a distinctive…

WednesdayMay 13, 2026 9:00 am

CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research

BioMedWire Editorial Coverage: Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain barrier (“BBB”), a specialized biological membrane, shields neural tissue from foreign substances, including most therapeutic agents. As cases of Alzheimer's disease climb worldwide and governments sharpen their focus on biodefense, the absence of efficient pathways for delivering drugs to the brain is fast becoming one of medicine's most pressing unresolved problems. Companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) are responding to this challenge with next-generation delivery platforms engineered to circumvent biological barriers and ensure direct,…

WednesdayMay 13, 2026 9:00 am

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (“T2DM”) rank among the most urgent and costly healthcare problems facing the world today, contributing to surging rates of cardiovascular disease, fatty liver disease, kidney complications and ballooning healthcare expenses. What once represented a specialized class of diabetes treatments has grown into one of the most consequential therapeutic categories in modern medicine, with GLP-1 receptor agonists now fundamentally restructuring how obesity, metabolic disease and potentially even neurodegeneration are treated. Operating in this environment is SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (Profile), which through its subsidiary GlucaPharm Inc. is developing a…

MondayMay 11, 2026 9:00 am

CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities

BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (“CNS”). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile), are working within a broader industry shift toward advanced delivery platforms designed to…

MondayMay 11, 2026 9:00 am

The Next Generation of the GLP-1 Revolution Is Already Underway

BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (“T2DM”) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), (Profile) through its subsidiary GlucaPharm Inc., is advancing a differentiated next-generation GLP-1 platform centered on GEP-44, a novel…

MondayMay 11, 2026 9:00 am

The Future of Intoxication Detection May Be in Your Voice

BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement and workplace safety to healthcare and public health management. Traditional methods such as breathalyzers, blood tests and urine screenings are often limited by their invasiveness, delayed results or inability to assess real-time impairment, particularly in cases involving multiple substances. As patterns of substance use evolve and the societal costs of impaired behavior continue to rise, the demand for faster, more scalable and noninvasive diagnostic solutions is becoming increasingly urgent. MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) (Profile) is…

WednesdayApr 22, 2026 9:00 am

Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition

BioMedWire Editorial Coverage: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is supported by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to incorporate clinical progress, probability of success and expected commercialization timelines into measurable balance sheet value. Companies at the…

MondayApr 20, 2026 9:00 am

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector historically defined by long timelines and uncertain outcomes. As drug candidates advance closer to commercialization, scientific progress is no longer viewed solely as research expenditure but increasingly as a measurable financial asset. This shift is being reinforced by fair-value accounting under U.S. GAAP, which allows life sciences companies to reflect clinical progress, probability of success and commercialization timing as measurable balance sheet value. Leading companies, such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile), are keenly aware of this evolution and…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Brand Awareness

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

How Advanced Drug Delivery Could Improve Existing Cancer Treatments

Real-Time Intoxication Detection Platforms Target Expanding Multibillion-Dollar Healthcare Opportunities

CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities

The Next Generation of the GLP-1 Revolution Is Already Underway

The Future of Intoxication Detection May Be in Your Voice

Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search